Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference in New York City.
https://mma.prnewswire.com/media/557290/Theravance_Biopharma_Logo.jpg
Rick Winningham, CEO, will participate in a Fireside Chat on Tuesday, September 9at1:30 PM EDT(10:30 AM PDT/6:30 PM IST).
Management will be hosting in-person meetings during the event. Interested investors should contact their H.C. Wainwright representative to request a meeting.
A live webcast of the event may be accessed here or on the “Events and Presentation” page under the Investors section on Theravance.com. A replay of the webcast will be archived on the Company's website for 30 days.
AboutTheravance Biopharma
Theravance Biopharma, Inc.'sfocus is to deliverMedicines that Make a Difference®in people's lives. In pursuit of its purpose,Theravance Biopharmaleverages decades of expertise, which has led to the development of FDA-approved YUPELRI®(revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visitwww.theravance.com.THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of theTheravance Biopharmagroup of companies (in theU.S.and certain other countries).
YUPELRI® is a registered trademark ofViatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact:investor.relations@theravance.com650-808-4045
https://c212.net/c/img/favicon.png?sn=SF62929&sd=2025-09-02
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302543498.html
SOURCE Theravance Biopharma, Inc.
https://rt.newswire.ca/rt.gif?NewsItemId=SF62929&Transmission_Id=202509020600PR_NEWS_USPR_____SF62929&DateId=20250902